Scarica l'app Stockscreener
64.46
4.45%
2.8269
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$61.63
Aprire:
$61.79
Volume 24 ore:
6.46M
Relative Volume:
1.37
Capitalizzazione di mercato:
$24.83B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
27.57
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+8.50%
1M Prestazione:
+0.62%
6M Prestazione:
+6.99%
1 anno Prestazione:
-24.69%
Intervallo 1D:
$61.54
$65.17
Intervallo di 1 settimana:
$57.66
$65.17
Portata 52W:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
64.36 | 23.78B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.36 | 147.13B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
313.27 | 117.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
77.02 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.80 | 78.30B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.11 | 46.86B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
Dexcom stock (US2521311074): Analyst moves follow Elliott deal and new long-term targets - AD HOC NEWS
DexCom Stock Jumps As 2030 Targets Ignite Bullish Trading - StocksToTrade
Dexcom Reveals Flex CGM for Type 2 Diabetes Patients - Medical Product Outsourcing
DexCom (DXCM) Introduces Dexcom Flex for Type 2 Diabetes Patients - GuruFocus
DexCom, Inc. Stock 12‑Month Price Target Cut to $82.28, Implies 34% Upside - TradingView
Wearables in Pharma & Biotech Research and Forecasts Report 2026-2031, Company Profiles and Market Strategies of Abbott, Dexcom, and Masimo - Yahoo Finance
BofA Securities Adjusts Price Target on DexCom to $80 From $100 - marketscreener.com
Redefining CGM for People With Type 2 Diabetes: Dexcom Announces Dexcom Flex in Germany - The Joplin Globe
DexCom Stock Jumps After Diabetes Management Firm Reaches Agreement With Elliott Investment Management - TIKR.com
Dexcom Inc. stock (US2521311074): diabetes tech player in focus after recent share move - AD HOC NEWS
DexCom, Inc. (DXCM) Analyst/Investor DaySlideshow (NASDAQ:DXCM) 2026-05-17 - Seeking Alpha
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
Elliott strikes Dexcom board settlement after taking stake - MSN
symbol__ Stock Quote Price and Forecast - CNN
Stephens Investment Management Group LLC Boosts Stock Position in DexCom, Inc. $DXCM - MarketBeat
Assessing DexCom (DXCM) Valuation After Investor Day Targets And New US$1b Buyback Plan - Yahoo Finance
Did New Long-Term Targets and US$1 Billion Buyback Just Shift DexCom's (DXCM) Investment Narrative? - Yahoo Finance
Here's why you should hold DexCom stock in your portfolio for now - MSN
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day - sharewise.com
DexCom Stock Jumps As 2030 Growth Targets And Buybacks Ignite Bullish Momentum - timothysykes.com
DexCom (DXCM) Unveils Ambitious Financial Targets and Share Repu - GuruFocus
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DNB Asset Management AS Boosts Position in DexCom, Inc. $DXCM - MarketBeat
Bank Julius Baer & Co. Ltd Zurich Sells 98,913 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom (DXCM) Posts Upbeat 2026, Climbs 6.6% - Insider Monkey
DexCom Inc (DXCM) Shares Surge 6.6% -- What GF Score of 88 Tells Investors - GuruFocus
Michael Brown reports two 1,700-share DXCM sales through Morgan Stanley (DXCM) - Stock Titan
Dexcom to add 2 board directors with activist investor Elliott - MedTech Dive
DexCom (DXCM) Shares Rise 5.5% Amid Market Decline - GuruFocus
DexCom (DXCM) Is Trending on Elliott’s Deal, but Execution Is Still the Real Story - AlphaStreet
Diabetes Tech Player DexCom Lays Out 2030 Growth VisionDexCom (NASDAQ:DXCM) - Benzinga
Dexcom, Inc. (DXCM) 8-K SEC Filing Details: Company Info, Address, and Trading Information (May 14, 2026) - Minichart
Why is DexCom stock surging today? By Investing.com - Investing.com Canada
DexCom Long-Range Plan Establishes Respectable Base Case, RBC Says - Moomoo
Elliott Takes Dexcom Stake in Bet on Glucose Monitors Market - Bloomberg.com
DexCom DXCM Draws Bullish Analyst Wave As Governance Shifts - timothysykes.com
Barclays Cuts DexCom Price Target to $64 From $67, Maintains Underweight Rating - marketscreener.com
Dexcom stock (US2521311074): 2030 targets and $1 billion buyback in focus - AD HOC NEWS
DexCom Expects Organic Revenue Growth of Above 10% Per Year Through 2030 - Moomoo
DexCom Stock Draws Bullish Targets As Governance Shifts - StocksToTrade
Piper Sandler reiterates Dexcom stock rating after investor meeting By Investing.com - Investing.com
Here's Why DexCom (DXCM) is a Strong Value Stock - Yahoo Finance
Truist reiterates Buy on DexCom stock, cites growth potential By Investing.com - Investing.com Canada
Canaccord Genuity Adjusts DexCom Price Target to $82 From $100, Maintains Buy Rating - marketscreener.com
DexCom, Inc. announces an Equity Buyback for $1,000 million worth of its shares. - marketscreener.com
Tranche Update on DexCom, Inc.'s Equity Buyback Plan announced on May 1, 2025. - marketscreener.com
Benchmark reaffirms Dexcom stock rating after growth strategy event - Investing.com
Are Wall Street Analysts Bullish on DexCom’s Stock? - Barchart.com
DXCM: DexCom Sees Strong Premarket Gains Amid Market Declines - GuruFocus
Dexcom Unveils 2030 Targets and $1 Billion Buyback - TipRanks
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Heller Bridgette P | Director |
May 12 '26 |
Sale |
60.01 |
1,012 |
60,730 |
25,007 |
3.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):